MedTrace Logo

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

NCT03093168 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-02-27

No results posted yet for this study

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

Conditions

Interventions

BIOLOGICAL

Anti-BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

DRUG

Fludarabine

dose: 25mg/m2/d

DRUG

Cyclophosphamide

Dose: 40mg/kg

Sponsors & Collaborators

  • Hrain Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2019-09-30
Completion
2020-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03093168 on ClinicalTrials.gov